Curosurf (poractant alfa) 120 mg/1.5 mL suspension for intratracheal administration, 1 vial (Chiesi) Distress syndrome in preterm infants Drug delivery from Europe and beyond, with strict storage conditions, payment upon receipt, and orders by calling +380996042415, Viber, or WhatsApp.

240 MG 1 FL - 380

 

Display.

- Treatment of respiratory distress syndrome in premature newborns.

- Prevention of respiratory distress syndrome in children with risk of development of respiratory distress syndrome (RDS).

Method of congestion and dosage.

Intratracheal insertion by intubation children on artificial ventilation devices with continuous monitoring of heart rate, acid concentration in the arterial bed, or acid saturation.

Treatment must be started as soon as possible after diagnosis of respiratory distress syndrome. Before drying, the bottle is heated to 37?C, carefully turn it upside down until it burns, and do not get scared. The suspension is collected from a vial with a series of sterile tips and syringes and administered through a catheter intratracheally at the lower end of the trachea. The baby should be turned on its side for the shortest distribution of surfactant in the upper leg. After skin injection, manual ventilation of the leg is carried out with a stretch of 1 - 2 strokes. with a concentration of inhaled acid that is comparable to the output of the device.

Likuvannya. Set the single dose at 100 – 200 mg/kg (1.25 – 2.5 ml/kg); if necessary, take one or two additional half doses – 100 mg/kg at an interval of 12 years. The maximum dose is 300 – 400 mg/kg.

Prevention. The drug in a single dose of 100 – 200 mg/kg (1.25 – 2.5 ml/kg) must be administered over the first 15 minutes. after the people of the child. Another dose of the drug, 100 mg/kg, should be administered after 6 to 12 years. If a diagnosis of respiratory distress syndrome is made and there is a need for individual ventilation, the drug should be administered at a 12-year interval. The maximum dose is 300 – 400 mg/kg.